Endovascular Aneurysm Repair Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Endovascular Aneurysm Repair Market Trends and Insights

Growing Burden of Aortic Aneurysm Disease

Rising life expectancy and expanded abdominal imaging are lifting the diagnosed prevalence faster than declines in cardiovascular mortality, feeding a steady inflow of repair candidates. The Global Burden of Disease Study 2024 recorded an 8% rise in age-standardized abdominal aortic aneurysm prevalence between 2019 and 2024 in high-income regions^{[1]Institute for Health Metrics and Evaluation, “GBD 2024 Aortic Conditions,” healthdata.org}. Screening programs in the United Kingdom and Scandinavia now identify aneurysms below the historical 5.5 cm threshold, creating a watchful-waiting cohort that matures into a cohort with interventional demand. China’s 2025 national survey found an undiagnosed abdominal aneurysm in 1.8% of men over 65, equal to roughly 3 million latent cases. These epidemiologic data underpin procedure stability even when per-case reimbursement stagnates. The endovascular aneurysm repair market, therefore, benefits from sheer patient volume growth rather than price escalation.

Shift Toward Minimally Invasive Vascular Interventions

Patient preference for shorter stays is accelerating the pivot from open surgery to catheter-based repair. Medicare claims showed that 78% of intact abdominal repairs were endovascular in 2024, versus 72% in 2020^{[2]Centers for Medicare & Medicaid Services, “National Summary of Inpatient Claim Statistics 2024,” cms.gov}. Percutaneous closure devices eliminated the need for surgical cutdown in 85% of cases by 2025, reducing the median length of stay to 1.2 days. Society for Vascular Surgery guidelines published in 2025 formally endorsed outpatient repair for low-risk anatomy, codifying a practice that burgeoned during pandemic bed shortages. Device makers responded with 14- to 16-French delivery systems that widen access to older patients with calcified femoral arteries. Consequently, the endovascular aneurysm repair market is seeing rising procedural volume even amid flat overall aneurysm incidence curves.

Advancements in Stent-Graft Engineering and Materials

Polymer-covered grafts made from ultra-high-molecular-weight polyethylene showed 30% lower fatigue in bench tests than their polyester predecessors. Laser-cut scallops and conformable nitinol frameworks enable off-the-shelf fenestrated and branched options, reducing lead times from 6 weeks to under 2 days. The FDA’s January 2024 clearance of Gore’s EXCLUDER Thoracic Branch Endoprosthesis marked the first mass-produced branched device in the United States. Conformable neck-sealing technology lowered type-Ia endoleak rates from 8% to below 3% in registries, strengthening payer confidence. These engineering gains elevate technical success and fortify the long-term competitiveness of the endovascular aneurysm repair market.

Expansion of Outpatient Endovascular Treatment Centers

CMS added CPT 34701 to the ambulatory-surgery-center list in January 2024, reimbursing USD 8,200 per case compared with USD 14,500 in hospital outpatient departments. Private-equity-backed ASC chains opened 47 vascular-focused centers in 2025, each outfitted with fixed C-arms and rapid-recovery bays. Manufacturers now run mobile training units that bring simulation labs to community surgeons, lowering the credentialing hurdle. A multicenter trial published in 2024 documented no rise in 30-day complications for same-day discharge EVAR, reinforcing payer acceptance. Lower facility overhead and bundled device-closure contracts amplify margin potential, making ASCs a structurally advantaged node of the endovascular aneurysm repair market.

High Total Cost of Endovascular Procedures

Device outlays account for up to 70% of the episode cost, straining budgets in the absence of comprehensive insurance coverage. A 2024 JAMA Surgery analysis pegged incremental cost per quality-adjusted life year above USD 75,000 in octogenarians with comorbidities, a level that exceeds willingness-to-pay thresholds in several EU systems^{[3]JAMA Network Editors, “Cost-Effectiveness of EVAR in Octogenarians,” jamanetwork.com}. India’s national plan reimburses only USD 3,500, forcing patients to shoulder USD 8,000-12,000 for branded grafts. China split its market: imported devices remain 2.5 times as expensive as local equivalents, preserving a two-tier supply chain. Hospitals in lower-income settings often revert to open repair because total consumable costs are under USD 500. These affordability hurdles temper adoption rates and cap short-term growth of the endovascular aneurysm repair market.

Durability and Long-Term Surveillance Uncertainties

The U.K. EVAR-1 trial’s 15-year data showed equivalent aneurysm mortality between EVAR and open surgery, but triple the number of secondary interventions in the endovascular group. Lifelong CT or duplex surveillance adds USD 800 annually, layering costs on top of the initial premium. European payers now tie reimbursement to registry participation, delaying payment and adding administrative burdens. Radiation exposure exceeding 100 mSv over a decade also raises patient safety concerns. Younger patients face the prospect of multiple reinterventions, weakening the perceived value of the endovascular aneurysm repair market for that cohort.

Segment Analysis

By Indication: AAA Dominance Persists Amid TAA Acceleration

Abdominal repairs accounted for 75.43% of 2025 revenue, reflecting decades of device iteration, standardized sizing algorithms, and broad surgeon familiarity. Thoracic interventions, though smaller, are advancing at a 6.43% CAGR as branched and fenestrated grafts unlock arch and dissection cases that previously defaulted to open repair. The U.S. FDA’s April 2025 approval of Gore’s TAG Thoracic Branch Endoprosthesis gave operators a ready solution for zone-0 and zone-1 disease, reducing planning time and stroke risk. Expanded trauma indications and dissection-specific devices further energize thoracic growth. Consequently, the endovascular aneurysm repair market is gradually rebalancing toward more complex thoracic volumes even while abdominal repairs remain the procedural bedrock.

Procedure complexity shapes revenue intensity. AAA cases, typically performed in community hospitals, rely on off-the-shelf infrarenal grafts with commodity-level pricing. TAA procedures are concentrated in academic centers with hybrid rooms and advanced imaging, which command higher average selling prices. Device miniaturization is beginning to push thoracic work into select ambulatory settings, mirroring the pattern of abdominal migration. As these technological and organizational shifts converge, the endovascular aneurysm repair market size attributable to thoracic pathology is set to rise faster than the traditional abdominal segment, driving mix-driven revenue uplift over the forecast horizon.

Note: Segment shares of all individual segments available upon report purchase

By Site: Infrarenal Procedures Lead, Pararenal Cases Surge

Infrarenal aneurysms accounted for 65.32% of the 2025 case volume, owing to favorable neck anatomy that suits standard grafts and streamlined workflows. Pararenal repairs, however, are forecast to grow at a 7.11% CAGR to 2031 as off-the-shelf fenestrated platforms eliminate lengthy customization delays. Cook Medical’s Zenith Fenestrated graft reached U.S. hospitals in 2025, trimming lead times from six weeks to mere days. Post-deployment data show 94% technical success, bringing outcomes closer to open surgery benchmarks.

Volume migration is also driven by chimney and snorkel adjuncts that enable community surgeons to tackle short-neck lesions without resorting to open repair. Payers increasingly accept fenestrated pricing, given reductions in ICU stay and transfusion rates. As a result, the endovascular aneurysm repair market for pararenal anatomy is likely to gain share within the broader infrarenal-dominant landscape, reshaping stocking priorities for hospital supply chains.

By Anatomy: Complex Repairs Gain Traction Through Modular Innovation

Traditional anatomy still made up 60.65% of 2025 cases, yet complex configurations are expanding at a 6.23% CAGR as modular graft designs and imaging fusion techniques improve success rates. Gore’s EXCLUDER Conformable AAA device, cleared for high-angle necks in 2024, achieved 96% freedom from aneurysm-related mortality at one year among hostile neck patients. Variable-stiffness nitinol lets the graft adapt to conical morphology, slashing type-Ia endoleaks below 4%.

Physician-modified grafts remain an interim solution for urgent cases pending formal branched approvals. Societal guidelines now call for standardized reporting of such modifications to inform future device development. Imaging innovation, particularly CT-fluoroscopy fusion, reduces contrast load and shortens procedure time. As operator learning curves flatten, the endovascular aneurysm repair market share linked with complex anatomy is set to climb steadily, albeit from a smaller base than standard neck repairs.

By Product: Percutaneous Systems Command Share, Fenestrated Devices Accelerate

Percutaneous systems held 44.32% revenue in 2025, thanks to sutureless closure devices that facilitate same-day discharge. Medicare’s outpatient list expansion in January 2024 generated an immediate reimbursement tailwind. Thoracic grafts mirror abdominal product evolution but retain higher average selling prices because of longer lengths and branch options. Fenestrated systems, though niche, are forecast to grow at a 6.87% CAGR and command USD 25,000-35,000 per unit, more than double the price of standard infrarenal grafts.

Manufacturers race to lower sheath profiles while embedding pre-loaded guidewires to cut cath-lab time. Adjunct tools such as iliac-branch extensions and embolic coils add incremental revenue per case. Within this dynamic, the endovascular aneurysm repair market size tied to premium fenestrated offerings is set to outpace the broader product pool, boosting blended average selling prices despite commoditization pressure in infrarenal lines.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Retain Majority, ASCs Capture Growth

Hospitals accounted for 62.13% of global end-user spend in 2025, driven by hybrid suites, intensive care support, and multidisciplinary teams. Complex thoracic or pararenal anatomy typically mandates in-house vascular or cardiothoracic backup. Nevertheless, ambulatory surgical centers are projected for 7.54% CAGR growth, buoyed by lower facility fees and payer push toward cost efficiency. Straightforward infrarenal repairs with ASA class I–II patients transition smoothly to the outpatient model.

Private-equity capital continues to fund vessel-specific ASC rollouts that pair imaging with procedure and surveillance under one roof. Device companies deploy mobile simulation trailers to certify ASC physicians without travel downtime. As health systems rebalance care sites, the endovascular aneurysm repair market share held by ASCs will expand, though hospitals will remain indispensable for high-acuity care and training.

Geography Analysis

North America retained 43.12% of 2025 revenue, underpinned by Medicare stability, dense specialist concentration, and a robust registry ecosystem that validates device safety. CMS approval of percutaneous closure in ASCs catalyzed outpatient migration, increasing overall procedural accessibility even as hospital margins compressed. Canada lags because single-payer budgets limit hybrid-suite throughput, leading to longer wait times that skew ruptured aneurysm repairs toward EVAR to mitigate mortality.

Europe contributes a sizable but heterogeneous slice of the endovascular aneurysm repair market. Germany’s DRG incentives drive EVAR penetration above 80% for elective abdominal cases, whereas the United Kingdom balances NICE endorsement of fenestrated repair with NHS budget caps that confine complex procedures to designated centers. France’s 12% device price cut enacted in 2025 pushed manufacturers into volume discounts. Southern and Eastern European uptake remains constrained by limited capital expenditure, but EU Medical Device Regulation harmonization maintains consistent safety standards, reinforcing confidence in imported grafts.

Asia-Pacific is the fastest-growing region at 5.54% CAGR, anchored by China, India, and Japan. China’s bulk-purchase program closed price gaps for domestic devices, opening tier-2 cities and stimulating training initiatives. India’s metro-based private chains invest in hybrid rooms to court medical tourists, while Japan leans on universal coverage but negotiates aggressive price concessions. Australia and South Korea follow mature-market patterns but at smaller volumes. Collectively, emerging economies rely on infrastructure gains and declining device prices to unlock deferred demand, ensuring that the endovascular aneurysm repair market expands beyond its traditional strongholds.